• 1
    Surveillance, Epidemiology, and End Results (SEER) Program ( SEER*Stat Database: Mortality—All COD, Public-Use With State, Total U.S. for Expanded Races/Hispanics (1990–2001), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2004. Underlying mortality data provided by NCHS (Available at URL: 2004.
  • 2
    U.S. Census Bureau. Current population survey, 2002 to 2004 annual social and economic supplements. Washington, DC: U.S. Census Bureau. Available at URL: [Accessed 2004].
  • 3
    Bishaw A, Iceland J. Poverty:1999. In: U. S. Census Bureau. Census 2000 Brief Series, C2KBR-19. Washington, DC: U.S. Census Bureau, 2003.
  • 4
    U.S. Census Bureau. Population by race and Hispanic or Latino origin, for all ages and for 18 years and over, for the United States: 2000. Washington, DC: U.S. Census Bureau, published online January 21, 2005. Available at URL:
  • 5
    Ward E, Jemal A, Cokkinides V, et al. Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin. 2004; 54: 7893.
  • 6
    National Institutes of Health. Public Law 103–43, the National Institutes of Health Revitalization Act of 1993. 1993: 103143.
  • 7
    Adams-Campbell LL, Ahaghotu C, Gaskins M, et al. Enrollment of African Americans onto clinical treatment trials: study design barriers. J Clin Oncol. 2004; 22: 730734.
  • 8
    HarrisInteractive. Misconceptions and lack of awareness greatly reduce recruitment for cancer clinical trials. January 22, 2001;1: Available at URL: [accessed November 2005].
  • 9
    Hussain-Gambles M, Atkin K, Leese B. Why ethnic minority groups are under-represented in clinical trials: a review of the literature. Health Soc Care Community. 2004; 12: 382388.
  • 10
    Hutchins L, Unger J, Crowley J, Coltman C, Albain K. Underrepresentation of patients 65 years of age older in cancer treatment trials. N Engl J Med. 1999; 341: 20612067.
  • 11
    Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004; 291: 27202726.
  • 12
    Newman LA, Hurd T, Leitch M, et al. A report on accrual rates for elderly and minority-ethnicity cancer patients to clinical trials of the American College of Surgeons Oncology Group. J Am Coll Surg. 2004; 199: 644651.
  • 13
    Sateren WB, Trimble EL, Abrams J, et al. How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. J Clin Oncol. 2002; 20: 21092117.
  • 14
    Simon MS, Du W, Flaherty L, et al. Factors associated with breast cancer clinical trials participation and enrollment at a large academic medical center. J Clin Oncol. 2004; 22: 20462052.
  • 15
    Swanson GM, Bailar JC 3rd. Selection and description of cancer clinical trials participants—science or happenstance? Cancer. 2002; 95: 950959.
  • 16
    Tejeda HA, Green SB, Trimble EL, et al. Representation of African-Americans, Hispanics, and whites in National Cancer Institute cancer treatment trials. J Natl Cancer Inst. 1996; 88: 812816.
  • 17
    American Joint Commission on Cancer. AJCC comparison guide: cancer staging manual fifth versus sixth edition. New York: Springer Verlag, 2004.
  • 18
    Peterson ED, Lytle BL, Biswas MS, Coombs L. Willingness to participate in cardiac trials. Am J Geriatr Cardiol. 2004; 13: 1115.
  • 19
    Beswick AD, Rees K, Griebsch I, et al. Provision, uptake and cost of cardiac rehabilitation programmes: improving services to under-represented groups. Health Technol Assess. 2004; 8: iiiiv, ix–x, 1–152.
  • 20
    Bartlett C, Davey P, Dieppe P, Doyal L, Ebrahim S, Egger M. Women, older persons, and ethnic minorities: factors associated with their inclusion in randomised trials of statins 1990 to 2001. Heart. 2003; 89: 327328.
  • 21
    Heiat A, Gross CP, Krumholz HM. Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med. 2002; 162: 16821688.
  • 22
    Alvidrez J, Arean PA. Psychosocial treatment research with ethnic minority populations: ethical considerations in conducting clinical trials. Ethics Behav. 2002; 12: 103116.
  • 23
    Miskimen T, Marin H, Escobar J. Psychopharmacological research ethics: special issues affecting US ethnic minorities. Psychopharmacology (Berl). 2003; 171: 98104.
  • 24
    Miranda J, Nakamura R, Bernal G. Including ethnic minorities in mental health intervention research: a practical approach to a long-standing problem. Cult Med Psychiatry. 2003; 27: 467486.
  • 25
    Gifford AL, Cunningham WE, Heslin KC, et al. Participation in research and access to experimental treatments by HIV-infected patients. N Engl J Med. 2002; 346: 13731382.
  • 26
    Betancourt JR. Cultural competence—marginal or mainstream movement? N Engl J Med. 2004; 351: 953955.
  • 27
    Chirikos TN, Ruckdeschel JC, Krischer JP. Impact of clinical trials on the cost of cancer care. Med Care. 2001; 39: 373383.
  • 28
    Fireman BH, Fehrenbacher L, Gruskin EP, Ray GT. Cost of care for patients in cancer clinical trials. J Natl Cancer Inst. 2000; 92: 136142.
  • 29
    Bennett CL, Stinson TJ, Vogel V, et al. Evaluating the financial impact of clinical trials in oncology: results from a pilot study from the Association of American Cancer Institutes/Northwestern University clinical trials costs and charges project. J Clin Oncol. 2000; 18: 28052810.
  • 30
    Gaskin DJ, Hadley J. Population characteristics of markets of safety-net and nonsafety-net hospitals. J Urban Health. 1999; 76: 351370.
  • 31
    U.S. Census Bureau. U.S. Interim projections by age, sex, race, and Hispanic origin. Washington DC: U.S. Census Bureau, published online March 18, 2004. Available at URL: